Construction method and application of stably transfected firefly luciferase target cell strain

By constructing a stable firefly luciferase target cell line, the problems of high equipment requirements and unstable data of traditional immune cell killing efficiency detection methods are solved, and the killing activity determination of immune cell with simple operation, low background and stable data are achieved, improving the The research and development efficiency of immune cell therapy technology.

CN119020422AInactive Publication Date: 2024-11-26KUNMING MEDICAL UNIVERSITY

Patent Information

Application Number
CN202411512660.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-28
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The traditional immune cell killing efficiency detection methods have problems such as high equipment requirements, high detection background, large signal-to-noise ratio, cumbersome operation, and unstable data, which seriously restricts the research and development and clinical application of immune cell therapy technology.

Method used

By constructing a stable firefly luciferase target cell line, the target gene plasmid pCDH-CMV-MCS-EF1-copGFP-T2A-Puro skeleton plasmid and pSELECT-zeo-LucSh plasmid were used for molecular cloning and homologous recombination, and the target gene plasmid pCDH was obtained by obtaining the target gene plasmid pCDH -CMV-LucSh(CpG-free)-EF1-copGFP-T2A-Puro, lentiviral packaging and transfection were performed, and target cell lines co-expressing firefly luciferase, GFP and resistance screening markers were obtained for immune cells Determination of killing activity.

Benefits of technology

It realizes a simple, efficient and fast detection of immune cell killing activity, which has the characteristics of low background, stable data, small system and low equipment requirements, and improves the research and development efficiency and reliability of immune cell therapy technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020422A_ABST
    Figure CN119020422A_ABST
Patent Text Reader

Abstract

The invention discloses a construction method and application of a stably transfected firefly luciferase target cell strain, and relates to the technical field of cellular immunotherapy, pCDH-CMV-MCS-EF1-copGFP-T2A-Puro is taken as a skeleton plasmid, an MCS region is recombined into a LucSh (CpG-free) gene sequence by means of molecular cloning and homologous recombination, a target gene plasmid pCDH-CMV-LucSh (CpG-free)-EF1-copGFP-T2A-Puro is obtained, then lentivirus packaging and transfection are carried out, and the stable transfected firefly luciferase target cell strain is obtained. The stably transfected firefly luciferase target cell strain co-expressed with the firefly luciferase, the GFP and the resistance selection marker can be obtained, and the stably transfected firefly luciferase target cell strain can be applied to determination of efficiency of killing target cells by immune cells and has the characteristics of low background, stable data, small system, simplicity in operation and low equipment requirement.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cell immunotherapy, and in particular to a method for constructing a stably transfected firefly luciferase target cell line and an application thereof. Background Art

[0002] In recent years, with the enrichment of immunology theory and the understanding of many tumor antigens, immune cell therapy has made breakthrough progress in the clinical application of tumor treatment. As of now, there are more than a thousand tumor immune cell therapy programs under development worldwide. Innate immune cells such as γδT, NK, NKT, M1 macrophages and acquired immune cell therapy technologies such as CIK, tumor infiltrating T lymphocytes (TIL), genetically engineered T cells (CAR-T, TCR-T), and tumor neoantigen-cytotoxic T lymphocyte therapy (Neo-CTL) have made breakthrough progress in the treatment of various tumors. Immune cell therapy technology has become the most concerned direction in the development of tumor treatment technology.

[0003] In the process of research and development of immune cell therapy technology, cell killing experiments are a very critical verification method in the process of research and development of immune cell therapy technology. Its technical stability, ease of operation, and reliability of results are of decisive significance for evaluating the preparation quality of immune cells and the killing efficiency of infusion back into the body. In traditional classic immune cell killing efficiency detection, such as 51 chromium (Cr) release method and lactate dehydrogenase (LDH) release method, there are many unfavorable factors such as high equipment requirements, high detection background, large signal-to-noise ratio, cumbersome operation, unstable data, etc., which seriously restrict the research and development and clinical application of immune cell therapy technology. Summary of the invention

[0004] The purpose of the present invention is to provide a method for constructing a stably transfected firefly luciferase target cell line, which is simple to operate, efficient and fast, and can construct a stably transfected target cell line that co-expresses three genes of firefly luciferase, GFP and a resistance screening marker, and has a positive rate close to 100%.

[0005] Another object of the present invention is to provide an application of a stably transfected firefly luciferase target cell line, which can be used for the determination of immune cell killing activity and has the characteristics of low background, stable data, small system, simple operation and low equipment requirements.

[0006] The embodiment of the present invention is achieved as follows: A method for constructing a stably transfected firefly luciferase target cell line, comprising: Using pCDH-CMV-MCS-EF1-copGFP-T2A-Puro as the backbone plasmid and pSELECT-zeo-LucSh as the target plasmid, the LucSh (CpG-free) gene sequence in the target plasmid was constructed into the MCS region of the backbone plasmid by molecular cloning and homologous recombination to obtain the target gene plasmid, i.e., pCDH-CMV-LucSh(CpG-free)-EF1-copGFP-T2A-Puro; The target gene plasmid is packaged with lentivirus to obtain virus liquid; The virus solution was used to infect tumor-derived target cells, and target cell lines stably expressing firefly luciferase were screened and obtained.

[0007] The invention discloses an application of a stably transfected firefly luciferase target cell line in the determination of immune cell killing activity. The stably transfected firefly luciferase target cell line is obtained by the above-mentioned construction method.

[0008] The beneficial effects of the embodiments of the present invention are: The invention provides a construction method and application of a stably transfected firefly luciferase target cell strain. The method uses pCDH-CMV-MCS-EF1-copGFP-T2A-Puro as a backbone plasmid, recombines an MCS region into a LucSh (CpG-free) gene sequence by molecular cloning and homologous recombination to obtain a target gene plasmid pCDH-CMV-LucSh(CpG-free)-EF1-copGFP-T2A-Puro, and then performs lentivirus packaging and transfection to obtain a stably transfected firefly luciferase target cell strain co-expressing firefly luciferase, GFP and a resistance screening marker. The stably transfected firefly luciferase target cell strain can be used for determining the efficiency of immune cells killing target cells, and has the characteristics of low background, stable data, small system, simple operation and low equipment requirements. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0010] Figure 1 Fluorescence images (upper image) and actual images (lower image) of three stably transfected firefly luciferase target cell lines provided in Example 3 of the present invention; Figure 2 The flow cytometry GFP results of K562-Luc-GFP provided in Example 3 of the present invention; Figure 3 The GFP results of the flow cytometry of Raji-Luc-GFP provided in Example 3 of the present invention; Figure 4 The flow cytometry GFP results of Nalm6-Luc-GFP provided in Example 3 of the present invention; Figure 5 The luminescence value measurement results of the three stably transfected firefly luciferase target cell lines provided in Experimental Example 1 of the present invention; Figure 6 The results of measuring the luminescence values ​​of two stably transfected firefly luciferase target cell lines as a function of cell number provided in Experimental Example 1 of the present invention; Figure 7 The luminescence value test result of the stably transfected firefly luciferase target cell line provided in Application Example 1 of the present invention applied to the NK cell killing activity assay; Figure 8 The results of the killing activity assay of the stably transfected firefly luciferase target cell line provided in Application Example 1 of the present invention applied to the killing activity assay of NK cells; Fig. 9 The luminescence value measurement result of the stably transfected firefly luciferase target cell line provided in Application Example 1 of the present invention applied to the CAR-T cell killing activity measurement; Fig.10 The killing activity assay results of the stably transfected firefly luciferase target cell line provided in Application Example 1 of the present invention applied to the killing activity assay of CAR-T cells. DETAILED DESCRIPTION

[0011] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0012] The following is a detailed description of a method for constructing a stably transfected firefly luciferase target cell line and its application in an embodiment of the present invention.

[0013] The present invention provides a method for constructing a stably transfected firefly luciferase target cell line, which comprises: S1. Using pCDH-CMV-MCS-EF1-copGFP-T2A-Puro as the backbone plasmid and pSELECT-zeo-LucSh as the target plasmid, the LucSh (CpG-free) gene sequence in the target plasmid was constructed into the MCS region of the backbone plasmid by molecular cloning and homologous recombination to obtain the target gene plasmid, i.e., pCDH-CMV-LucSh(CpG-free)-EF1-copGFP-T2A-Puro; S2. packaging the target gene plasmid with lentivirus to obtain virus liquid; S3. Use the virus solution to infect tumor-derived target cells and screen to obtain target cell lines stably transfected with firefly luciferase.

[0014] Among them, pCDH-CMV-MCS-EF1-copGFP-T2A-Puro plasmid and pSELECT-zeo-LucSh plasmid are both commercialized plasmids and can be purchased directly from channels for use.

[0015] Optionally, the above step S1 specifically includes: S1-1. Linearize the backbone plasmid using a linearization primer; S1-2. The target plasmid was amplified by PCR using gene amplification primers to obtain the LucSh (CpG-free) gene sequence; S1-3. Under the action of homologous recombinase, the LucSh (CpG-free) gene sequence is recombined and replaced with the MCS region of the linearized backbone plasmid to obtain the target gene plasmid.

[0016] The linearization primers include 42#-Line-F and 42#-Line-R, wherein the nucleotide sequence of 42#-Line-F is as described in SEQ ID NO: 1, specifically: GCTAGCGAATTCGAATTTAAATC.

[0017] The nucleotide sequence of 42#-Line-R is shown in SEQ ID NO:2, specifically: TCTAGAATCTTCTATGGAGG.

[0018] The gene amplification primers include LucSh(CpG-free)-F and LucSh(CpG-free)-R, wherein the nucleotide sequence of LucSh(CpG-free)-F is shown in SEQ ID NO:3, specifically: CCTCCATAGAAGATTCTAGAATGGAGGATGCCAAGAATATTAAGAAAG.

[0019] The nucleotide sequence of LucSh(CpG-free)-R is shown in SEQ ID NO:4, specifically: GATTTAAATTCGAATTCGCTAGCTCAGTCCTGCTCCTCTGCCAC.

[0020] Furthermore, the target gene plasmid was sequenced and verified by sequencing primers, the sequencing primer was CMV-F, and its nucleotide sequence was shown in SEQ ID NO:5, specifically: GGTAGGCGTGTACGGTGG.

[0021] Furthermore, the nucleotide sequence of the LucSh (CpG-free) gene fragment is shown in SEQ ID NO: 6. The nucleotide sequence of the copGFP-T2A-Puro gene fragment is shown in SEQ ID NO: 7.

[0022] Furthermore, in the above step S2, the target cell plasmid and the packaging plasmid are transfected into 293T cells for lentiviral packaging, and the packaging plasmids include pSPAX2 and pMD2G. Among them, the packaging plasmids pSPAX2 and pMD2G are mature products that can be directly obtained through commercial channels. The lentiviral packaging adopts the calcium phosphate method, wherein the mass ratio of the target cell plasmid and pSPAX2 and pMD2G is 4:3:1.

[0023] Further, in the above step S3, the tumor-derived target cells include any one of K562, Raji and Nalm6. The infected tumor-derived target cells are screened by GFP and puromycin to screen positive cells to obtain a stably transfected firefly luciferase target cell line. Corresponding to different tumor-derived target cells, the stably transfected firefly luciferase target cell lines obtained are Raji-Luc-GFP, K562-Luc-GFP and Nalm6-Luc-GFP, respectively.

[0024] The embodiment of the present invention also provides an application of a stably transfected firefly luciferase target cell line in the determination of immune cell killing activity. The stably transfected firefly luciferase target cell line is obtained by the above-mentioned construction method.

[0025] Optionally, the specific determination method includes: The target cell line stably expressing firefly luciferase was mixed with immune cells (effector cells) for 24-48 h, the supernatant was removed by centrifugation, and then lysis buffer and firefly luciferin substrate were added; after incubation for 15-20 min, the chemiluminescence value was detected.

[0026] Furthermore, the chemiluminescence value is detected by using a chemiluminescence instrument or an enzyme-labeled instrument with a chemiluminescence detection module, and the detection can be completed within the wavelength range of 380~780nm. The detection result is calculated by the following formula: Immune cell killing activity = (1-luminescence value of experimental group / luminescence value of control group) × 100% Among them, the luminescence value of the experimental group refers to the luminescence value measured by lysing the target cell line stably transfected with firefly luciferase and immune cells after mixed culture; the luminescence value of the control group refers to the luminescence value measured by lysing the equal amount of target cell line stably transfected with firefly luciferase after single culture.

[0027] The background value of this assay is extremely low and can be basically ignored, so there is no need to deduct the background value (the spontaneous luminescence value of target cells and effector cells without lysis). The experimental system is small and the calculation formula is simpler. The lysis solution and firefly luciferin substrate required for the test can be configured by yourself, which greatly reduces the test cost. At the same time, the monitoring wavelength of this assay is wide, and detection can be completed in the wavelength range of 380~780nm. It has high sensitivity and can still accurately detect even when there are 5000 cells.

[0028] In comparison, in the traditional lactate dehydrogenase (LDH) method, it is necessary to set up spontaneous groups of target cells and effector cells, and the luminescence value of the spontaneous group needs to be deducted when performing calculations. Especially when performing multiple effect-target ratio tests, each effect-target ratio needs to have a separate spontaneous group. Therefore, both the operational difficulty and the calculation difficulty are higher than the determination method provided by the present invention. In addition, the traditional LDH method can only be detected at a wavelength of 490nm, and the sensitivity is relatively low. The materials in the test process use a kit, which is more expensive.

[0029] Furthermore, the immune cells used in the present invention include but are not limited to any one of CAR-T cells and NK cells. It should be noted that for those skilled in the art, without departing from the precursor of the method of the present invention, the improvement and supplement of the firefly luciferase target cells established for other immune cells and the determination of the killing efficiency of immune cells using the system should also be regarded as the protection scope of the present invention.

[0030] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0031] Example 1 This embodiment provides a method for preparing a target gene plasmid pCDH-CMV-MCS-EF1-copGFP-T2A-Puro, which comprises: The backbone plasmid pCDH-CMV-MCS-EF1-copGFP-T2A-Puro was linearized using linearization primers 42#-Line-F and 42#-Line-R; The target plasmid pSELECT-zeo-LucSh was amplified by PCR using the gene amplification primers LucSh(CpG-free)-F and LucSh(CpG-free)-R to obtain the LucSh (CpG-free) gene sequence; Under the action of homologous recombinase, the LucSh (CpG-free) gene sequence was recombined and replaced with the MCS region of the linearized backbone plasmid. The recombination temperature was 37°C and the duration was 30 minutes to obtain the target gene plasmid pCDH-CMV-MCS-EF1-copGFP-T2A-Puro.

[0032] Example 2 This embodiment provides a lentiviral packaging method for a target cell plasmid pCDH-CMV-MCS-EF1-copGFP-T2A-Puro, which comprises: 1) Reagent preparation: Viral packaging plasmid: pSPAX2 / pMD2G.

[0033] Transfection reagent: 1000X chloroquine solution (100mmol / L): 52mg chloroquine diphosphate (Shanghai Shenggong Cat: C6569) was dissolved in 1mL deionized water, filtered through 0.22μm for sterilization, and stored at -20℃ away from light.

[0034] CaCl2: 2.5 M 2x BBS: 1.636 g NaCl (Sigma Cat: S7653), 1.065 g BES (Sigma Cat: B4554), 0.021 g Na2HPO4 (Sigma Cat: S5136), H2O to 90 mL, adjust pH to about 6.95 (1 M NaOH), make up to 100 mL, and store at 4°C.

[0035] Complete medium: DMEM + 10% FBS-PS.

[0036] 2) Packaging process 10cm, 293T cell number: 4x10 6 , each dish was filled with 10cm DMEM + 10% FBS-PS complete medium, cultured until the next day for use, and the cell density was controlled at about 80%~90%.

[0037] Prepare transfection reagent and change the medium (1000X chloroquine solution with a final concentration of 100μmol / L, 7ml, DMEM + 2% FBS culture medium). Chloroquine can inhibit cell growth, causing it to produce more viruses, while inhibiting cell autophagy and plasmid degradation.

[0038] The packaging plasmid and transfection reagent were prepared into a Ca-DNA mixed solution, and the mixture was allowed to stand for 3 minutes after mixing. The Ca-DNA mixed solution included 50 μl of CaCl2 (2.5M), 12 μg of the target gene plasmid of Example 1, 9 μg of Pspax2, and 3 μg of PMD2.0G, and was adjusted to a total volume of 500 μl with nuclease-free water.

[0039] Slowly vortex and add an equal volume (500ul) of 2x BBS to the Ca-DNA mixture, vortex the round-bottom centrifuge tube for 10 seconds, mix thoroughly and let it stand for 15 minutes.

[0040] The vortexed mixture was evenly dripped into the culture dish containing complete medium. The 10 cm dish was shaken crosswise 6-8 times and then placed in a 37°C, 5% CO2 incubator for incubation. After incubation for 6 hours, the medium was replaced with 10 ml of DMEM + 2% FBS per well.

[0041] The virus supernatant was collected twice at 36h and 60h, respectively, based on the time point of changing the liquid. The supernatant was filtered through a 0.45um filter to obtain the virus solution. The virus solution was divided into 500ul / tube and frozen at -80℃.

[0042] Concentrate the virus solution by ultracentrifugation (80000xg) at 20℃ for 2h. Resuspend in DPBS and control the concentration rate between 100x-200x. Then dispense at 20-50ul / tube.

[0043] Example 3 This embodiment provides a method for constructing a target cell line stably transfected with firefly luciferase, comprising: Cell plating: 24-well plate, Raji / K562 / Nalm6 cell number: 1x10 5 cells / well. After the cells are plated, they can be infected. Each well contains 500uL complete culture medium and 500ul of the virus solution provided in Example 2.

[0044] Medium change: After 24 hours, remove the supernatant and add 1 ml of fresh DMEM + 10% FBS medium; continue culturing for 72 hours.

[0045] Resistance screening: After removing the supernatant, add 1 ml of fresh DMEM + 10% FBS medium containing 2 ug / ml puromycin and continue culturing for 72 h to obtain the stably transfected firefly luciferase target cell lines Raji-Luc-GFP, K562-Luc-GFP and Nalm6-Luc-GFP. Figure 1 The fluorescence images (above) and actual images (below) of three stably transfected firefly luciferase target cell lines are shown.

[0046] GFP was measured by flow cytometry, referring to Figures 2~4 As shown, the positive rates of the three types of cells screened were 94.3%, 98.1% and 93.8%, respectively.

[0047] Test Example 1 The stably transfected firefly luciferase target cell lines Raji-Luc-GFP, K562-Luc-GFP and Nalm6-Luc-GFP prepared in Example 3, as well as the corresponding tumor-derived target cells Raji, K562 and Nalm6, were used to culture the cells at a cell number of 1×10 6 The chemiluminescence value was measured under the conditions of Figure 5 shown.

[0048] It can be seen that the luminescence values ​​of the three stably transfected firefly luciferase target cell lines are all as high as about 60,000, while the luminescence values ​​of the three tumor-derived target cells are less than 20. It can be seen that the background values ​​brought by the three tumor-derived target cells are extremely small and can be basically ignored. Therefore, when using it to measure the killing activity of immune cells, there is no need to set the background value for subtraction, which can greatly simplify the operation process and calculation difficulty of the measurement.

[0049] Test Example 2 The stably transfected firefly luciferase target cell lines Raji-Luc-GFP and K562-Luc-GFP prepared in Example 3 were used to culture the cells at different cell numbers (5×10 4 , 1×10 4 , 5×10 3 , 1×10 3 ) and measure its luminescence value. The measurement results are as follows Figure 6 shown.

[0050] Depend on Figure 6 It can be seen that when the cell number is reduced to 5×10 3 At the same time, the luminescence values ​​of the two stably transfected firefly luciferase target cell lines can still reach more than 1000, and can still be used to measure the killing activity of immune cells, showing ultra-high sensitivity.

[0051] Application Example 1 The stably transfected firefly luciferase target cell line (K562-Luc-GFP) prepared in Example 3 was used to determine the killing activity of NK cells. The specific steps are as follows: For the 96-well plate, an opaque flat-bottom plate was selected, and the number of target cells was 5000 cells / 96 wells, with 4 replicate wells. The plated cells were divided into two components, 5000 target cells, and the target cells and effector cells were cultured in four ratios of 1:1, 5:1, 10:1, and 20:1. After 24 hours of culture, the supernatant was removed by centrifugation, and then the lysis solution and firefly luciferin substrate were added to the cells. After incubation for 15-20 minutes, the chemiluminescence value was detected in a chemiluminometer or an enzyme reader with a chemiluminescence detection module (380-780nm can be measured). The chemiluminescence values ​​were used to calculate the immune cell killing activity values ​​at four ratios of 1:1, 5:1, 10:1, and 20:1. The test results are as follows: Figure 7-8 shown.

[0052] Figure 7 The luminescence values ​​measured at different effector-target ratios are shown. It can be seen from the figure that the luminescence background values ​​of NK cells with different cell numbers are close to 0 and can be ignored. As the effector-target ratio increases, the luminescence value shows a decreasing trend. Figure 8 The killing activity values ​​of immune cells under different effector-target ratios are shown. It can be seen that the killing activity values ​​of immune cells show an increasing trend with the increase of effector-target ratio. The entire test method has good stability and sensitivity.

[0053] Application Example 2 The stably transfected firefly luciferase target cell lines K562-Luc-GFP and Raji-Luc-GFP prepared in Example 3 were used to determine the killing activity of CAR-T cells. The specific operation steps were carried out with reference to Application Example 1. The determination results are shown in FIG. Figures 9 and 10 shown.

[0054] Fig. 9 The luminescence values ​​measured at different effector-target ratios are shown in the figure. As can be seen from the figure, with the increase of the effector-target ratio, the luminescence value and immune cell killing activity value of the K562-Luc-GFP experimental group remained basically unchanged, which shows that CAR-T cells have a significant effect on K562 cells (CD19 - ) cell lines had no killing efficiency. Fig.10 The killing activity values ​​of immune cells under different effector-target ratios are shown. As the effector-target ratio increases, the luminescence value of the Raji-Luc-GFP experimental group shows a decreasing trend, and the killing activity value of immune cells shows an increasing trend, indicating that CAR-T cells have a positive effect on Raji cells (CD19 + ) can obtain stable and sensitive effector cell killing activity measurement values.

[0055] In summary, the present invention provides a method for constructing a stably transfected firefly luciferase target cell strain and its application, which uses pCDH-CMV-MCS-EF1-copGFP-T2A-Puro as a backbone plasmid, and recombines the MCS region into a LucSh (CpG-free) gene sequence by molecular cloning and homologous recombination to obtain a target gene plasmid pCDH-CMV-LucSh(CpG-free)-EF1-copGFP-T2A-Puro, and then through lentiviral packaging and transfection, a stably transfected firefly luciferase target cell strain co-expressing firefly luciferase, GFP and a resistance screening marker can be obtained. The stably transfected firefly luciferase target cell strain can be used for the determination of the efficiency of immune cells killing target cells, and has the characteristics of low background, stable data, small system, simple operation and low equipment requirements.

[0056] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for constructing a stably transfected firefly luciferase target cell line, characterized in that: include: Using pCDH-CMV-MCS-EF1-copGFP-T2A-Puro as a backbone plasmid and pSELECT-zeo-LucSh as a target plasmid, the LucSh (CpG-free) gene sequence in the target plasmid was constructed into the MCS region of the backbone plasmid by molecular cloning and homologous recombination to obtain a target gene plasmid, i.e., pCDH-CMV-LucSh (CpG-free) -EF1-copGFP-T2A-Puro; Packaging the target gene plasmid with lentivirus to obtain virus liquid; The virus liquid is used to infect tumor-derived target cells, and the stably transfected firefly luciferase target cell line is screened and obtained.

2. The construction method according to claim 1, characterized in that: include: Linearizing the backbone plasmid using a linearization primer; The target plasmid is amplified by PCR using gene amplification primers to obtain the LucSh (CpG-free) gene sequence; Under the action of homologous recombinase, the LucSh (CpG-free) gene sequence is recombined and replaced with the MCS region of the linearized backbone plasmid to obtain the target gene plasmid.

3. The construction method according to claim 2, characterized in that: The linearized primers include 42#-Line-F and 42#-Line-R, and their nucleotide sequences are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

4. The construction method according to claim 2, characterized in that: The gene amplification primers include LucSh(CpG-free)-F and LucSh(CpG-free)-R, and their nucleotide sequences are shown in SEQ ID NO:3 and SEQ ID NO:4, respectively.

5. The construction method according to claim 2, characterized in that: The target gene plasmid is sequenced and verified by a sequencing primer, wherein the sequencing primer is CMV-F, and its nucleotide sequence is shown in SEQ ID NO:

5.

6. The construction method according to claim 1, characterized in that: The target cell plasmid and packaging plasmid are transfected into 293T cells together for lentiviral packaging. The packaging plasmid includes pSPAX2 and pMD2G. The mass ratio of the target cell plasmid to pSPAX2 and pMD2G is 4:3:

1.

7. The construction method according to claim 1, characterized in that: The tumor-derived target cells include any one of K562, Raji and Nalm6.

8. The construction method according to claim 7, characterized in that: The tumor-derived target cells after infection are screened for GFP and positive cells are screened for puromycin to obtain the stably transfected firefly luciferase target cell line.

9. Application of a stably transfected firefly luciferase target cell line in the determination of immune cell killing activity, characterized in that: The stably transfected firefly luciferase target cell line is obtained by the construction method according to any one of claims 1 to 8.

10. The use according to claim 9, characterized in that: The immune cells include any one of CAR-T cells and NK cells.

Citation Information

Patent Citations

  • Recombinant lentivirus vector and preparation method and application thereof

    CN107012173A

  • Method for constructing stable cell strain secreting expression protein

    CN107043786A

  • Genetic engineering of macrophages for immunotherapy

    CN108243607A

  • Preparation method and application of anti-tumor microparticles modified by genetic engineering

    CN111420031A

  • Dual-luciferase reporter gene vector regulated and controlled by interferon stimulation response element as well as construction method and application of dual-luciferase reporter gene vector

    CN116837027A

Cited By

  • Cell composition, preparation method and application thereof

    CN119432734A